If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2015

Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma

Seggewiss-Bernhardt, R., Bargou, R. C., Goh, Y. T., Stewart, A. K., Spencer, A., Alegre, A., Blade, J., Ottman, O. G., Fernandez-Ibarra, C., Lu, H., Pain, S., Akimov, M. & Iyer, S. P., 2015, In : Cancer. 121, 13, p. 2185 - 2192 8 p.

Research output: Contribution to journalArticleResearchpeer-review

24 Citations (Scopus)

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Scheid, C., Reece, D. E., Beksac, M., Spencer, A., Callander, N. S., Sonneveld, P., Kalimi, G., Cai, C., Shi, M. M., Scott, J. W. & Stewart, A. K., 2015, In : European Journal of Haematology. 95, 4, p. 316 - 324 9 p.

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Revised international staging system for multiple myeloma: a report from international myeloma working group

Palumbo, A., Avet-Loiseau, H., Olivia, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P. G., Caltagirone, S., Lahuerta, J. J., Facon, T., Bringhen, S., Gay, F., Attal, M., Passera, R., Spencer, A., Offidani, M., Kumar, S. K., Musto, P., Lonial, S., Petrucci, M. T. & 11 others, Orlowski, R. Z., Zamagni, E., Morgan, G., Dimopoulos, M. A., Durie, B. G. M., Anderson, K. C., Sonneveld, P., San Miguel, J. F., Cavo, M. M., Rajkumar, S. V. & Moreau, P., 2015, In : Journal of Clinical Oncology. 33, 26, p. 2863 - 2869 7 p.

Research output: Contribution to journalArticleOther

594 Citations (Scopus)

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit

Harrison, S. J. A., Quach, H., Link, E. K., Feng, H., Dean, J., Copeman, M. B., van de Velde, H., Schwarer, A., Baker, B., Spencer, A., Catalano, J., Campbell, P., Augustson, B. M., Romeril, K. & Prince, H. M., 2015, In : American Journal of Hematology. 90, 5, p. 86 - 91 6 p.

Research output: Contribution to journalArticleOther

5 Citations (Scopus)

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

Diel, I. J., Body, J-J., Stopeck, A. T., Vadhan-Raj, S., Spencer, A., Steger, G., von Moos, R., Goldwasser, F., Feng, A. & Braun, A., 2015, In : European Journal of Cancer. 51, 11, p. 1467-1475 9 p.

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: Position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S. J., Mollee, P., Roberts, A. W., Horvath, N., Talulikar, D., To, B., Zannettino, A., Brown, R., Catley, L., Augustson, B., Jaksic, W., Gibson, J. & Prince, H. M., Jan 2015, In : Internal Medicine Journal. 45, 1, p. 94-105 12 p.

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: Position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group (

Quach, H., Joshua, D. E., Ho, J., Szer, J., Spencer, A., Harrison, S., Mollee, P. N., Roberts, A. W., Horvath, N., Talaulikar, D., To, B., Zannettino, A. C. W., Brown, R. D., Catley, L. P., Augustson, B. M., Jaksic, W. J., Gibson, J. L. & Prince, H. M., 2015, In : Internal Medicine Journal. 45, 3, p. 335-343 9 p.

Research output: Contribution to journalArticleOtherpeer-review

2 Citations (Scopus)
2014
36 Citations (Scopus)

Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia

Doan, T. N., Kong, D. C. M., Patel, K., Walker, P. A., Spencer, A. & Kirkpatrick, C. M. J., 2014, In : International Journal of Antimicrobial Agents. 44, 5, p. 450 - 457 8 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Tan, P., Wei, A., Mithraprabhu, S., Cummings, N. J., Liu, H. B., Perugini, M., Reed, K. D., Avery, S., Patil, S., Walker, P. A., Mollee, P. N., Grigg, A. P., D'Andrea, R. J., Dear, A. E. & Spencer, A., 2014, In : Blood Cancer Journal. 4, 1, p. 1 - 8 8 p., e170.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
72 Citations (Scopus)

Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

Mithraprabhu, S., Kalff, A., Chow, A., Khong, T. T. F. & Spencer, A., 2014, In : Epigenetics. 9, 11, p. 1511 - 1520 10 p.

Research output: Contribution to journalArticleResearchpeer-review

65 Citations (Scopus)

Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: Analysis of 344 patients

Bryant, A., Nivison-Smith, I., Pillai, ES., Kennedy, G., Kalff, A., Ritchie, D., George, B., Hertzberg, M., Patil, S., Spencer, A., Fay, K., Cannell, P., Berkahn, L., Doocey, R., Spearing, R. & Moore, J., Jan 2014, In : Bone Marrow Transplantation. 49, 1, p. 17-23 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
9 Citations (Scopus)

Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia

Fedele, P., Avery, S., Patil, S., Spencer, A., Haas, M. & Wei, A., 2014, In : Internal Medicine Journal. 44, 8, p. 757 - 763 7 p.

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation

Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A. T., Niesvizky, R., Morgan, G., Landgren, O., Hajek, R., Einsele, H., Anderson, K. C., Dimopoulos, M. A., Richardson, P. G., Cavo, M. M., Spencer, A., Stewart, A. K., Shimizu, K., Lonial, S., Sonneveld, P., Durie, B. G. M., Moreau, P. & 1 others, Orlowski, R. Z., 2014, In : Journal of Clinical Oncology. 32, 6, p. 587-600 14 p.

Research output: Contribution to journalArticleResearchpeer-review

218 Citations (Scopus)

Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies

Liu, H. B., Urbanavicius, D. B., Tan, P., Spencer, A. & Dear, A. E., 2014, In : International journal of oncology. 45, 4, p. 1742 - 1748 7 p.

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)
Open Access
11 Citations (Scopus)

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

San Miguel, J. F., Blade, J., Shpilberg, O., Grosicki, S., Maloisel, F., Min, C-K., Zarzuela, M. P., Robak, T., Prasad, S. V. S. S., Goh, Y. T., Laubach, J. P., Spencer, A., Mateos, M. V., Palumbo, A., Puchalski, T. A., Reddy, M. P., Uhlar, C. M., Qin, X., van de Velde, H., Xie, H. & 1 others, Orlowski, R. Z., 2014, In : Blood. 123, 26, p. 4136 - 4142 7 p.

Research output: Contribution to journalArticleResearchpeer-review

86 Citations (Scopus)

Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients

Govindaraj, C., Tan, P., Walker, P. A., Wei, A., Spencer, A. & Plebanski, M., 2014, In : Clinical Cancer Research. 20, 3, p. 724 - 735 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
41 Citations (Scopus)

Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: A population-based cohort study

Bilmon, I. A., Ashton, L. J., Le Marsney, R. E., Dodds, A. J., O'Brien, T. A., Wilcox, L., Nivison-Smith, I., Daniels, B., Vajdic, C. M. & CAST study group, May 2014, In : Bone Marrow Transplantation. 49, 5, p. 691-698 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
16 Citations (Scopus)

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Palumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S. Z., Waage, A., Larocca, A. T., Van Der Holt, B. R., Musto, P., Offidani, M., Petrucci, M. T., Evangelista, A., Zweegman, S., Nooka, A. K., Spencer, A., Dimopoulos, M. A., Hajek, R., Cavo, M. M., Richardson, P. G., Lonial, S. & 6 others, Ciccone, G., Boccadoro, M., Anderson, K. C., Barlogie, B. M., Sonneveld, P. & McCarthy, P. L., 2014, In : The Lancet Oncology. 15, 3, p. 333 - 342 10 p.

Research output: Contribution to journalArticleResearchpeer-review

172 Citations (Scopus)

Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study

Kalff, A., Kennedy, N., Smiley, A., Miles Prince, H., Roberts, A. W., Bradstock, K., de Abreu Lourenço, R., Frampton, C. & Spencer, A., 2014, In : The Lancet Haematology. 1, 3, p. e112-e119 8 p.

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Spencer, A., Yoon, S-S., Harrison, S., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J. L. S., Kumar, R., Opalinska, J. B. & Chen, C., 2014, In : Blood. 124, 14, p. 2190 - 2195 6 p.

Research output: Contribution to journalArticleResearchpeer-review

73 Citations (Scopus)
2013

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia

Bishton, M. J., Spencer, A., Dickinson, M. J. & Ritchie, D., 2013, In : Clinical Lymphoma, Myeloma & Leukemia. 13, 5, p. 575 - 578 4 p.

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Central nervous system multiple myeloma - potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains

Lee, D., Kalff, A., Low, M., Gangatharan, S., Ho, P., Bajel, A., Ritchie, D., Grigg, A. & Spencer, A., 2013, In : British Journal of Haematology. 162, 3, p. 371 - 375 5 p.

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse

Fong, C. Y., Grigoriadis, G., Hocking, J., Coutsouvelis, J., Muirhead, J. L., Campbell, P., Paul, E., Walker, P. A., Avery, S., Patil, S., Spencer, A., Schwarer, A. & Wei, A., 2013, In : Leukemia and Lymphoma. 54, 2, p. 336 - 341 6 p.

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

High-dose cytarabine (24g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia

Low, M., Lee, D., Coutsouvelis, J., Patil, S., Opat, S., Walker, P. A., Schwarer, A., Salem, H. H., Avery, S., Spencer, A. & Wei, A., 2013, In : Internal Medicine Journal. 43, 3, p. 294 - 297 4 p.

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)
26 Citations (Scopus)

International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease

Terpos, E., Morgan, G., Dimopoulos, M. A., Drake, M. T., Lentzsch, S., Raje, N., Sezer, O., García-Sanz, R., Shimizu, K., Turesson, I., Reiman, T., Jurczyszyn, A., Merlini, G., Spencer, A., Leleu, X., Cavo, M. M., Munshi, N., Rajkumar, S. V., Durie, B. G. M. & Roodman, G. D., 20 Jun 2013, In : Journal of Clinical Oncology. 31, 18, p. 2347-2357 11 p.

Research output: Contribution to journalArticleOtherpeer-review

Open Access
File
205 Citations (Scopus)

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

Leow, C. C-Y., Gerondakis, S. D. & Spencer, A., 2013, In : Blood Cancer Journal. 3, p. 1 - 8 8 p., e105.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
40 Citations (Scopus)

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Deangelo, D. J., Spencer, A., Bhalla, K. N., Prince, H. M., Fischer, T., Kindler, T., Giles, F. J., Scott, J. W., Parker, K., Liu, A., Woo, M., Atadja, P., Mishra, K. K. & Ottmann, O. G., Aug 2013, In : Leukemia. 27, 8, p. 1628-1636 9 p.

Research output: Contribution to journalArticleResearchpeer-review

94 Citations (Scopus)

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

Dimopoulos, M., Siegel, D. S. D., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H. A., Goldschmidt, H., Hungria, V., Spencer, A., Palumbo, A., Graef, T., Eid, J. E., Houp, J., Sun, L., Vuocolo, S. C. & Anderson, K. C., 2013, In : The Lancet Oncology. 14, 11, p. 1129 - 1140 12 p.

Research output: Contribution to journalArticleResearchpeer-review

178 Citations (Scopus)
2012

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

Bensinger, W., Maziarz, R. T., Jagannath, S., Spencer, A., Durrant, S., Becker, P. S., Ewald, B., Bilic, S., Rediske, J., Baeck, J. & Stadtmauer, E. A., Oct 2012, In : British Journal of Haematology. 159, 1, p. 58-66 9 p.

Research output: Contribution to journalArticleResearchpeer-review

81 Citations (Scopus)

Failure of haematopoietic recovery overcome by SCT despite invasive mucormycosis infection

Grigoriadis, G., Chang, C. C., Walker, P., Patil, S., Avery, S., Morrissey, O. & Spencer, A., 2012, In : Bone Marrow Transplantation. 47, p. 591 - 592 2 p.

Research output: Contribution to journalArticleOtherpeer-review

1 Citation (Scopus)

How to manage neutropenia in multiple myeloma

Palumbo, A., Blade, J., Boccadoro, M., Palladino, C., Davies, F., Dimopoulos, M., Dmoszynska, A., Einsele, H., Moreau, P., Sezer, O., Spencer, A., Sonneveld, P. & Miguel, J., 2012, In : Clinical Lymphoma, Myeloma & Leukemia. 12, 1, p. 5 - 11 7 p.

Research output: Contribution to journalArticleResearchpeer-review

34 Citations (Scopus)

Lenalidomide in multiple myeloma: current status and future potential

Quach, H., Kalff, A. & Spencer, A., 2012, In : American Journal of Hematology. 87, 12, p. 1089 - 1095 7 p.

Research output: Contribution to journalArticleResearchpeer-review

20 Citations (Scopus)

MyelomA genetics international consortium

Morgan, G., Johnsen, H., Goldschmidt, H., Palumbo, A., Cavo, M., Sonneveld, P., Migel, J., Chim, C. S., Browne, P., Einsele, H., Waage, A., Turesson, I., Spencer, A., Hajek, R., Ludwig, H., Hemminki, K. & Houlston, R., 2012, In : Leukemia and Lymphoma. 53, 5, p. 796 - 800 5 p.

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination

Millward, M. J., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., Longenecker, A., Lee, L., Lay, A., Sharma, G., Gemmill, R. M., Drabkin, H. A., Lloyd, G. K., Neuteboom, S. T. C., McConkey, D. J., Palladino, M. A. & Spear, M. A., 2012, In : Investigational New Drugs. 30, 6, p. 2303 - 2317 15 p.

Research output: Contribution to journalArticleResearchpeer-review

92 Citations (Scopus)

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: Analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

Ho, P. J., Brown, R. D., Spencer, A., Jeffels, M., Daniher, D., Gibson, J. & Joshua, D. E., Sep 2012, In : Leukemia and Lymphoma. 53, 9, p. 1728-1734 7 p.

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies

Kalff, A. & Spencer, A., 2012, In : Blood Cancer Journal. 2, 9, p. 1 - 8 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
51 Citations (Scopus)
2011

Asparaginase in the management of adult acute lymphoblastic leukaemia: Is it used appropriately?

Patil, S., Coutsouvelis, J. & Spencer, A., 2011, In : Cancer Treatment Reviews. 37, 3, p. 202 - 207 6 p.

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

CYT997 causes apoptosis in human multiple myeloma

Monaghan, K., Khong, T., Smith, G. & Spencer, A., 2011, In : Investigational New Drugs. 29, 2, p. 232 - 238 7 p.

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome

Blade, J., Sonneveld, P., San Miguel, J., Sutherland, H., Hajek, R., Nagler, A., Spencer, A., Robak, T., Lantz, K., Zhuang, S., Harousseau, J. & Orlowski, R., 2011, In : Clinical Lymphoma, Myeloma & Leukemia. 11, 1, p. 44 - 49 6 p.

Research output: Contribution to journalArticleOther

27 Citations (Scopus)

Managing multiple myeloma in the elderly: Are we making progress?

Quach, H., Prince, M. & Spencer, A., 2011, In : Expert Review of Hematology. 4, 3, p. 301 - 315 15 p.

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

Palumbo, A., Bringhen, S., Ludwig, H., Dimopoilos, M., Blade, J., Mateos, M., Rosinol, L., Boccadoro, M., Cavo, M., Lokhorst, H., Zweegman, S., Terpos, E., Davies, F., Driessen, C., Gimsing, P., Gramatzki, M., Hajek, R., Johnsen, H., Leal Da Costa, F., Sezer, O. & 6 others, Spencer, A., Beksac, M., Morgan, G., Einsele, H., San Miguel, J. & Sonneveld, P., 2011, In : Blood. 118, 17, p. 4519 - 4529 11 p.

Research output: Contribution to journalArticleResearchpeer-review

221 Citations (Scopus)

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

Henry, D., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G., Sleeboom, H., Spencer, A., Vadhan-Raj, S., von Moos, R., Willenbacher, W., Woll, P., Wang, J., Qi, J., Jun, S., Dansey, R. & Yeh, H., 2011, In : Journal of Clinical Oncology. 29, 9, p. 1125 - 1132 8 p.

Research output: Contribution to journalArticleResearchpeer-review

778 Citations (Scopus)

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma

Khong, T. & Spencer, A., 2011, In : Molecular Cancer Therapeutics. 10, 10, p. 1909 - 1917 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
44 Citations (Scopus)

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells

Monaghan, K., Khong, T., Burns, C. & Spencer, A., 2011, In : Leukemia. 25, 12, p. 1891 - 1899 9 p.

Research output: Contribution to journalArticleOther

53 Citations (Scopus)

The role of the bone marrow microenvironment in multiple myeloma

Monaghan, K. & Spencer, A., 2011, In : European Journal of Clinical & Medical Oncology. 3, 2, p. 1 - 8 8 p.

Research output: Contribution to journalArticleResearchpeer-review

2010

Deactylase inhibition in myeloproliferative neoplasms

Mithraprabhu, S., Grigoriadis, G., Khong, T. & Spencer, A., 2010, In : Investigational New Drugs. 28, Suppl 1, p. 50 - 57 8 p.

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: Eighty-month follow-up

Patil, S., Spencer, A., Schwarer, A., Lewis, I., Hertzberg, M. S., Avery, S., Wei, A., Noutsos, T., Paul, E., Taouk, Y. & Muirhead, J. L., 2010, In : Bone Marrow Transplantation. 45, p. 1154 - 1160 6 p.

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)